<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-6-12892A0101-GGG-91010</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="SV">Svensk representation i IVIs styrelse 2019-2022</narrative>
   <narrative xml:lang="EN">Swedish representation on Board of IVI 2019-2022</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Sida/Sweden nominates and finances a representative of the International Vaccine Institute (IVI) Board of Trustees. The financing covers travel and salary costs for the representative of Sweden at  the Board meetings (2 physical meetings and four-five phone meeting per year). IVI has a mandate in the development of vaccins to poverty related diseases. The Swedish nominee needs thorough knowledge in drug discovery and development from both academia and industry, as well as knowledge of Sweden&apos;s priorities and research cooperation in international development cooperation.</narrative>
   <narrative xml:lang="SV">Sverige/Sida utser en svensk representant till International Vaccine Institute&apos;s (IVI&apos;s) styrelse. IVI utvecklar vaccin mot fattigdomsrelaterade sjukdomar. Sverige &#xE4;r stor givare till IVI, och kan genom deltagande i styrelsen driva fr&#xE5;gor av vikt f&#xF6;r Sverige. Det &#xE4;r viktigt att den utsedde personer har god k&#xE4;nnedom om svenska prioriteringar, h&#xE4;lsa, l&#xE4;kemedelsforskning och svenskt forskningssamarbete. 

Insatsen syftar till att finansiera arvodering och de resekostnader som uppkommer f&#xF6;r den utsedde svenska representanten f&#xF6;r sitt arbete i IVI&apos;s styrelse.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="SV">Sverige/Sida utser en svensk representant till International Vaccine Institute&apos;s (IVI&apos;s) styrelse. IVI utvecklar vaccin mot fattigdomsrelaterade sjukdomar. Sverige &#xE4;r stor givare till IVI, och kan genom deltagande i styrelsen driva fr&#xE5;gor av vikt f&#xF6;r Sverige. Det &#xE4;r viktigt att den utsedde personer har god k&#xE4;nnedom om svenska prioriteringar, h&#xE4;lsa, l&#xE4;kemedelsforskning och svenskt forskningssamarbete.</narrative>
  </description>
  <participating-org ref="11001" role="2">
   <narrative xml:lang="EN">Not applicable</narrative>
  </participating-org>
  <participating-org ref="11001" role="4" type="10">
   <narrative xml:lang="EN">Sida</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-6" role="3" type="10">
   <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2019-01-01" type="1"></activity-date>
  <activity-date iso-date="2019-01-01" type="2"></activity-date>
  <activity-date iso-date="2023-06-30" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
   </organisation>
   <telephone>+46 8 698 50 00</telephone>
   <email>sida@sida.se</email>
   <website>www.sida.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Valhallav&#xE4;gen 199, 105 25 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="910" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Administrative Costs of Donors</narrative>
  </sector>
  <sector code="91010" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Administrative costs (non-sector allocable)</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="G01" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">13524.7834685223</value>
  </budget>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">5773.152219942</value>
  </budget>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">11375.2054938264</value>
  </budget>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">25810.9573388987</value>
  </budget>
  <planned-disbursement>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">0</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">13524.7834685223</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">5773.152219942</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">11375.2054938264</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">25810.9573388987</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">52877.039731</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-04-28"></transaction-date>
   <value currency="USD" value-date="2019-04-28">1271.2697892321</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-07-28"></transaction-date>
   <value currency="USD" value-date="2019-07-28">6154.4749838725</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-10-28"></transaction-date>
   <value currency="USD" value-date="2019-10-28">832.813375776</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-12-28"></transaction-date>
   <value currency="USD" value-date="2019-12-28">5266.2380101312</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-07-28"></transaction-date>
   <value currency="USD" value-date="2020-07-28">2784.7161145314</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-12-28"></transaction-date>
   <value currency="USD" value-date="2020-12-28">2988.4762804434</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2021-09-28"></transaction-date>
   <value currency="USD" value-date="2021-09-28">5128.1185509916</value>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2021-12-28"></transaction-date>
   <value currency="USD" value-date="2021-12-28">6247.1242523522</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/12892_Beslutomtillaggtillbeslut2018-003799samt2019-001083omIVIBOTrepr.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om till&#xE4;gg till beslut 2018-003799 samt 2019-001083 om IVI BOT representant</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Results achieved</narrative>
    <narrative xml:lang="SV">Uppn&#xE5;dda resultat</narrative>
   </title>
   <description>
    <narrative xml:lang="SV">Under 2020 genomf&#xF6;rdes alla m&#xF6;ten p&#xE5; distans med gott resultat. Detta i sig &#xE4;r intressant, eftersom IVI f&#xF6;r n&#xE4;rvarande implementerar rekommendationer fr&#xE5;n den milj&#xF6;konsekvensanalys som f&#xE4;rdigst&#xE4;lldes 2019. Tidigare diskussioner har h&#xE5;llits om att ha ytterligare m&#xF6;ten p&#xE5; distans (styrelsen m&#xF6;ts vanligen p&#xE5; distans tv&#xE5; g&#xE5;nger per &#xE5;r och tv&#xE5; g&#xE5;nger fysiskt) men man trodde inte att det skulle fungera. Under pandemin har detta omv&#xE4;rderats och det &#xE5;terst&#xE5;r att se om det &#xE4;r m&#xF6;jligt att endast ha ett fysiskt m&#xF6;te per &#xE5;r fram&#xF6;ver.&#xA0;&#xC4;ven om distansm&#xF6;tena&#xA0;&#xE4;r kortare (3 timmar ist&#xE4;llet f&#xF6;r 2 dagar) har det varit effektivt, &#xE4;ven om det i l&#xE4;ngden sj&#xE4;lvklart&#xA0;inte g&#xE5;r att ers&#xE4;tta de fysiska m&#xF6;tena helt.
Under 2020 p&#xE5;b&#xF6;rjades ett arbete med att ta fram en ny strategi f&#xF6;r IVI, vilket diskuterades i styrelsen. V&#xE5;r representant trycker p&#xE5; behovet av att forts&#xE4;tta fokusera p&#xE5; l&#xE5;ginkomstl&#xE4;nder. Det h&#xE4;r &#xE4;r inte minst viktigt n&#xE4;r koreanska staten ibland vill se sina egna utmaningar omh&#xE4;ndertagna av institutet.&#xA0;
V&#xE5;r styrelserepresentant har ut&#xF6;ver sj&#xE4;lva styrelsem&#xF6;tena varit aktiv i en av styrelsens kommitt&#xE9;er (n&#xE5;got som f&#xF6;rv&#xE4;ntas av samtliga medlemmar), n&#xE4;mligen &quot;Benefit &amp; Compensation Committe&quot;. Det har varit extra v&#xE4;rdefullt f&#xF6;r Sida/Sveriges prioriteringar, eftersom det &#xE4;r d&#xE4;r man (f&#xF6;r styrelsens del) drivit fr&#xE5;gan av en genusanalys. IVI har i dialog med Sida och &#xE4;ven sj&#xE4;lva insett behovet av att arbeta med genusfr&#xE5;gan, men det har inte varit en sj&#xE4;lvklart fr&#xE5;ga f&#xF6;r styrelsen. Genom svensk representation i styrelsen har detta arbete kunnat genomf&#xF6;ras mycket mera effektivt och f&#xE5;tt st&#xF6;rre genomslag.&#xA0;
Ut&#xF6;ver detta har hon varit aktiv i kontakten med andra givare f&#xF6;r att engagera dem i IVI.&#xA0;
En rad fr&#xE5;gor belystes under 2020 och vi har haft diskussioner med v&#xE5;r representant regelbundet b&#xE5;de innan och efter olika m&#xF6;ten kopplade till IVI. IVI har varit av extra stort intresse internationellt under 2020 i och med pandemin, och dess styrelse har varit involverade i en rad strategiska beslut kopplade till detta. F&#xF6;r n&#xE4;rvarande samarbetar IVI med 10 olika vaccinutvecklare av covid-19 vaccin. IVI utvecklar inget eget covid-19&#xA0;vaccin, utan samarbetar med m&#xE5;let att tillgodose behoven i l&#xE5;g- och medelinkomstl&#xE4;nder p&#xE5; ett r&#xE4;ttvist s&#xE4;tt. Sidas st&#xF6;d till IVI rapporteras inom ramen f&#xF6;r dess insats och inte h&#xE4;r, d&#xE4;r fokus &#xE4;r p&#xE5; styrelserepresentationen.</narrative>
   </description>
   <indicator ascending="0" measure="5">
    <title>
     <narrative xml:lang="EN">Not applicable</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">No indicator available - only a description of the activity results is published</narrative>
    </description>
   </indicator>
  </result>
  <sida:contribution contributionid="12892" xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
  <sida:strategies xmlns:sida="http://sida.se/ns/strategies#">
   <sida:strategy code="1140102" currency="SEK" strategy-amount="0" strategy-end-date="2021-12-31" strategy-start-date="2015-01-01">
    <sida:title>Research cooperation 2015-2021</sida:title>
    <sida:titleSV>Forskningssamarbete 2015-2022</sida:titleSV>
   </sida:strategy>
  </sida:strategies>
 </iati-activity>
</iati-activities>
